US Patent

US10179120 — Dosage regimen of ferric trimaltol

Method of Use · Assigned to Iron Therapeutics Holdings AG · Expires 2035-01-06 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a dosage regimen of 30 mg of ferric trimaltol taken twice daily for treating iron deficiency with or without anaemia.

USPTO Abstract

The present invention relates to a dosage regimen of ST10 (ferric trimaltol) for the treatment of patients suffering from iron deficiency with or without anaemia. Specifically the invention relates to the treatment of patients with 30 mg ST10 twice daily.

Drugs covered by this patent

Accrufer (FERRIC MALTOL) · Shield Tx

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2603`	—	Accrufer

Patent Metadata

Patent number: US10179120
Jurisdiction: US
Classification: Method of Use
Expires: 2035-01-06
Drug substance claim: No
Drug product claim: No
Assignee: Iron Therapeutics Holdings AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.